Resveratrol Supplementation Did Not Improve Cognition in Patients with Schizophrenia: Results from a Randomized Clinical Trial.
BACKGROUND
Schizophrenia (SZ) is associated with psychotic experiences and cognitive deficits. Therefore, cognitive function is one of the most critical determinants of quality of life in this pathology. Resveratrol has been related to neuroprotective action, but there are no studies evaluating resveratrol in SZ. The objective of this study was to determine the efficacy of resveratrol supplementation on cognition in individuals with SZ.


METHODS
This is a 1-month randomized, double-blind, and controlled trial (NCT 02062190), in which 19 men with diagnosis of SZ, aged 18-65 years, were assigned to a resveratrol supplementation group (200 mg) or placebo group (200 mg), with a 1-month follow-up. Applying a series of cognitive tests assessed neuropsychology performance (Hopkins Verbal Learning Test, Stroop Color and Word Test, and Weschler Adult Intelligence Scale) and Brief Psychiatric Rating Scale assessed psychopathology severity.


RESULTS
There were no significant improvement in neuropsychology performance (episodic memory, working memory, attention and concentration capacity, inhibitory control, interference measures, selective attention, and mental flexibility) and psychopathology severity after 1 month of resveratrol supplementation (P> 0.05).


CONCLUSIONS
In conclusion, we have shown that 1 month of a resveratrol supplementation (200 mg/day) did not improve episodic memory, working memory, attention and concentration capacity, inhibitory control, interference measures, selective attention, and mental flexibility as compared with placebo in patients with SZ.
Schizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; Postgraduate Program in Medicine, Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Karine
K
Zortea
Schizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; Postgraduate Program in Medicine, Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Viviane C
VC
Franco
Postgraduate Program in Medicine, Psychiatry, Universidade Federal do Rio Grande do Sul , Porto Alegre, Rio Grande do Sul , Brazil.
Paula
P
Guimarães
Schizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; Postgraduate Program in Medicine, Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Paulo S
PS
Belmonte-de-Abreu
cognition; nutrients; nutritional requirements; polyphenols; resveratrol; schizophrenia
Diabetes. 2012 Jun;61(6):1444-54
22362175
J Neurosci. 2014 Jun 4;34(23):7862-70
24899709
Oxid Med Cell Longev. 2013;2013:419092
24163719
Am J Clin Nutr. 2010 Jun;91(6):1590-7
20357044
Br J Nutr. 2015 Nov 14;114(9):1427-37
26344014
Front Pharmacol. 2012 Jul 17;3:141
22822401
Int J Cardiol. 2015;189:47-55
25885871
Plant Foods Hum Nutr. 2015 Dec;70(4):454-62
26547323
Biochim Biophys Acta. 2015 Jun;1852(6):1202-8
25315300
Front Aging Neurosci. 2015 Jul 08;7:132
26217224
Annu Rev Clin Psychol. 2005;1:321-53
17716091
Biochim Biophys Acta. 2015 Jun;1852(6):1195-201
25281824
Mol Nutr Food Res. 2011 Aug;55(8):1129-41
21688389